{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:22:50Z","timestamp":1778617370795,"version":"3.51.4"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2020R1F1A1073114"],"award-info":[{"award-number":["2020R1F1A1073114"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004083","name":"Ministry of Science ICT and Future Planning","doi-asserted-by":"publisher","award":["NRF-2020M3A9B6038845"],"award-info":[{"award-number":["NRF-2020M3A9B6038845"]}],"id":[{"id":"10.13039\/501100004083","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003693","name":"Korea Institute of Science and Technology","doi-asserted-by":"publisher","award":["2Z06663"],"award-info":[{"award-number":["2Z06663"]}],"id":[{"id":"10.13039\/501100003693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.neo.2022.100817","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T12:34:59Z","timestamp":1658493299000},"page":"100817","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Patient-specific molecular response dynamics can predict the possibility of relapse during the second treatment-free remission attempt in chronic myelogenous leukemia"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3931-2805","authenticated-orcid":false,"given":"Eunjung","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eo-Jin","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junghye","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9584","key":"10.1016\/j.neo.2022.100817_bib0001","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Chronic myeloid leukaemia","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.neo.2022.100817_bib0002","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer","volume":"7","author":"Melo","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"23","key":"10.1016\/j.neo.2022.100817_bib0003","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.neo.2022.100817_bib0004","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","volume":"103","author":"Gambacorti-Passerini","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.neo.2022.100817_bib0005","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1182\/blood-2011-08-358135","article-title":"Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.neo.2022.100817_bib0006","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1158\/1078-0432.CCR-07-0844","volume":"13","author":"Branford","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.neo.2022.100817_bib0007","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.neo.2022.100817_bib0008","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12185-012-1093-y","article-title":"Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation","volume":"96","author":"Kim","year":"2012","journal-title":"Int J Hematol"},{"issue":"2","key":"10.1016\/j.neo.2022.100817_bib0009","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11899-016-0309-2","article-title":"Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"11","author":"Caldemeyer","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"issue":"5","key":"10.1016\/j.neo.2022.100817_bib0010","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/138920009788897975","article-title":"Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects","volume":"10","author":"Hartmann","year":"2009","journal-title":"Curr Drug Metab"},{"issue":"6","key":"10.1016\/j.neo.2022.100817_bib0011","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/ajh.23427","article-title":"Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib","volume":"88","author":"Lee","year":"2013","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.neo.2022.100817_bib0012","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.neo.2022.100817_bib0013","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.neo.2022.100817_bib0014","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.neo.2022.100817_bib0015","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1016\/j.ejca.2013.06.018","article-title":"Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON)","volume":"49","author":"Thielen","year":"2013","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.neo.2022.100817_bib0016","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3324\/haematol.2011.056853","article-title":"Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia","volume":"97","author":"Takahashi","year":"2012","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.neo.2022.100817_bib0017","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3324\/haematol.2015.139899","article-title":"Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study","volume":"101","author":"Lee","year":"2016","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.neo.2022.100817_bib0018","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.clml.2019.05.007","article-title":"Musculoskeletal pain in patients with chronic myeloid leukemia after tyrosine kinase inhibitor therapy cessation","volume":"19","author":"Kota","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement_1","key":"10.1016\/j.neo.2022.100817_bib0019","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1182\/blood-2019-131454","article-title":"BCR-ABL1 qPCR-based doubling time within the first 6 months after imatinib discontinuation is a predictive of successful TKI treatment-free remission","volume":"134","author":"Daher-Reyes","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.neo.2022.100817_bib0020","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.neo.2022.100817_sbref0021","first-page":"1196","article-title":"Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia","author":"Shanmuganathan","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.neo.2022.100817_bib0022","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1002\/ctm2.317","article-title":"A folate receptor 3 SNP promotes mitochondria-induced clonogenicity of CML leukemia cells: Implications for treatment free remission","volume":"11","author":"Shen","year":"2021","journal-title":"Clin Transl Med"},{"issue":"7046","key":"10.1016\/j.neo.2022.100817_bib0023","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","article-title":"Dynamics of chronic myeloid leukaemia","volume":"435","author":"Michor","year":"2005","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.neo.2022.100817_bib0024","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.3324\/haematol.2012.062844","article-title":"Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials","volume":"97","author":"Tang","year":"2012","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.neo.2022.100817_bib0025","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1182\/blood-2012-07-441956","article-title":"Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia","volume":"121","author":"Horn","year":"2013","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.neo.2022.100817_bib0026","doi-asserted-by":"crossref","first-page":"10302","DOI":"10.1073\/pnas.92.22.10302","article-title":"The purification and characterization of fetal liver hematopoietic stem-cells","volume":"92","author":"Morrison","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.neo.2022.100817_bib0027","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.cb.11.110195.000343","article-title":"The biology of hematopoietic stem cells","volume":"11","author":"Morrison","year":"1995","journal-title":"Ann Rev Cell Dev Biol"},{"issue":"2","key":"10.1016\/j.neo.2022.100817_bib0028","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/cdd.2014.89","article-title":"Regulation of hematopoietic and leukemic stem cells by the immune system","volume":"22","author":"Riether","year":"2015","journal-title":"Cell Death Differ"},{"issue":"3","key":"10.1016\/j.neo.2022.100817_bib0029","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1269\/jrr.19.262","article-title":"Incidence of leukemia in atomic bomb survivors belonging to a fixed cohort in Hiroshima and Nagasaki, 1950\u201371: radiation dose, years after exposure, age at exposure, and type of leukemia","volume":"19","author":"Ichimzru","year":"1978","journal-title":"J Radiat Res"},{"issue":"7501","key":"10.1016\/j.neo.2022.100817_bib0030","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nature13317","article-title":"Cell competition is a tumour suppressor mechanism in the thymus","volume":"509","author":"Martins","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.neo.2022.100817_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ydbio.2021.02.013","article-title":"Cell competition in hematopoietic cells: quality control in homeostasis and its role in leukemia","volume":"475","author":"Ramos","year":"2021","journal-title":"Dev Biol"},{"issue":"7","key":"10.1016\/j.neo.2022.100817_bib0032","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.cell.2019.04.040","article-title":"A cellular taxonomy of the bone marrow stroma in homeostasis and leukemia","volume":"177","author":"Baryawno","year":"2019","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.neo.2022.100817_bib0033","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.stem.2017.11.006","article-title":"Inhibition of endosteal vascular niche remodeling rescues hematopoietic stem cell loss in AML","volume":"22","author":"Duarte","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"6","key":"10.1016\/j.neo.2022.100817_bib0034","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.neo.2022.100817_bib0035","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/nm1487","article-title":"Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications","volume":"12","author":"Roeder","year":"2006","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.neo.2022.100817_bib0036","doi-asserted-by":"crossref","first-page":"476","DOI":"10.4252\/wjsc.v11.i8.476","article-title":"Bone marrow microenvironment: the guardian of leukemia stem cells","volume":"11","author":"Houshmand","year":"2019","journal-title":"World J Stem Cells"},{"issue":"6","key":"10.1016\/j.neo.2022.100817_bib0037","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1182\/blood-2011-02-339267","article-title":"Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells","volume":"118","author":"Tang","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.neo.2022.100817_bib0038","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1038\/bcj.2011.17","article-title":"A new hypothesis: imatinib affects leukemic stem cells in the same way it affects all other leukemic cells","volume":"1","author":"Tomasetti","year":"2011","journal-title":"Blood Cancer J"},{"issue":"9976","key":"10.1016\/j.neo.2022.100817_bib0039","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.neo.2022.100817_bib0040","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.3324\/haematol.2018.194522","article-title":"Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data","volume":"103","author":"Fassoni","year":"2018","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.neo.2022.100817_bib0041","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrclinonc.2016.139","article-title":"Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?","volume":"14","author":"Rosti","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.neo.2022.100817_bib0042","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1046\/j.1365-2141.2001.02858.x","article-title":"Estimating the relapse stage in chronic myeloid leukaemia patients after allogeneic stem cell transplantation by the amount of BCR-ABL fusion transcripts detected using a new real-time polymerase chain reaction method","volume":"113","author":"Elmaagacli","year":"2001","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.neo.2022.100817_bib0043","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood.V87.4.1549.bloodjournal8741549","article-title":"Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction","volume":"87","author":"Hochhaus","year":"1996","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.neo.2022.100817_bib0044","first-page":"160","article-title":"Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia","volume":"9","author":"Kantarjian","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.neo.2022.100817_bib0045","first-page":"361","article-title":"Regression trees with unbiased variable selection and interaction detection","volume":"12","author":"Loh","year":"2002","journal-title":"Stat Sin"},{"key":"10.1016\/j.neo.2022.100817_bib0046","first-page":"815","article-title":"Split selection methods for classification trees","volume":"7","author":"Loh","year":"1997","journal-title":"Stat Sin"},{"issue":"8","key":"10.1016\/j.neo.2022.100817_bib0047","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.patrec.2005.10.010","article-title":"An introduction to ROC analysis","volume":"27","author":"Fawcett","year":"2006","journal-title":"Pattern Recognit Lett"},{"issue":"6","key":"10.1016\/j.neo.2022.100817_bib0048","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.cell.2008.10.048","article-title":"Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair","volume":"135","author":"Wilson","year":"2008","journal-title":"Cell"},{"issue":"21","key":"10.1016\/j.neo.2022.100817_bib0049","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.1158\/1078-0432.CCR-11-0396","article-title":"BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment","volume":"17","author":"Stein","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.neo.2022.100817_bib0050","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.molonc.2010.06.001","article-title":"Targeting leukemic stem cells by breaking their dormancy","volume":"4","author":"Essers","year":"2010","journal-title":"Mol Oncol"},{"issue":"7","key":"10.1016\/j.neo.2022.100817_bib0051","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/s41375-019-0490-0","article-title":"Chronic myeloid leukemia stem cells","volume":"33","author":"Houshmand","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.neo.2022.100817_bib0052","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ccr.2011.10.012","article-title":"IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development","volume":"20","author":"Reynaud","year":"2011","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.neo.2022.100817_bib0053","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/leu.2015.45","article-title":"Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia","volume":"29","author":"Burchert","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.neo.2022.100817_sbref0054","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1158\/0008-5472.CAN-19-2175","article-title":"Model-based inference and classification of immunologic control mechanisms from TKI cessation and dose reduction in patients with CML","author":"Hahnel","year":"2020","journal-title":"Cancer Res"},{"issue":"21","key":"10.1016\/j.neo.2022.100817_bib0055","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.379.379","article-title":"Disease relapse after TKI discontinuation in CML is related both to low number and impaired function of NK-cells:data from Euro-SKI","volume":"122","author":"Ilander","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.neo.2022.100817_bib0056","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005803","article-title":"Clonal dominance and transplantation dynamics in hematopoietic stem cell compartments","volume":"13","author":"Ashcroft","year":"2017","journal-title":"PLoS Comput Biol"},{"issue":"18","key":"10.1016\/j.neo.2022.100817_bib0057","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1158\/0008-5472.CAN-20-0283","article-title":"Mathematical modeling provides evidence for niche competition in human AML and serves as a tool to improve risk stratification","volume":"80","author":"Stiehl","year":"2020","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.neo.2022.100817_bib0058","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1038\/s41598-018-21115-4","article-title":"Mathematical modeling of the impact of cytokine response of acute myeloid leukemia cells on patient prognosis","volume":"8","author":"Stiehl","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.neo.2022.100817_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtbi.2020.110499","article-title":"Effect of feedback regulation on stem cell fractions in tissues and tumors: Understanding chemoresistance in cancer","volume":"509","author":"Weiss","year":"2021","journal-title":"J Theor Biol"},{"issue":"4","key":"10.1016\/j.neo.2022.100817_bib0060","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \"good-risk\" chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.neo.2022.100817_bib0061","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1038\/s41375-020-0931-9","article-title":"The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia","volume":"34","author":"Pfirrmann","year":"2020","journal-title":"Leukemia"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558622000446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558622000446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:00:45Z","timestamp":1778616045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558622000446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":61,"alternative-id":["S1476558622000446"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2022.100817","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-specific molecular response dynamics can predict the possibility of relapse during the second treatment-free remission attempt in chronic myelogenous leukemia","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2022.100817","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100817"}}